Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a Type C meeting with the U.S. Food ...

Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on neflamapimod treatment for DLB New data demonstrating ...

A comprehensive study spanning a decade shed new light on the treatment of dementia with Lewy bodies (DLB), a condition that significantly impacts older adults. The research, published in Alzheimer’s ...

BOSTON, Aug. 22, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its recent ...

An estimated 10,000-12,000 people are living with Lewy body dementia in Ireland, but only a small number of sufferers get an accurate diagnosis ...

"This discovery is a huge step forward in our efforts to prevent dementia and neurovascular diseases." ...

Dementia with Lewy bodies is a type of dementia that is similar to both Alzheimer's disease and Parkinson's disease but studies on long-term treatments are lacking. A new study from Karolinska ...

Nilotinib (Tasigna) — a drug for myeloid leukemia — improved biomarkers and cognitive outcomes in study participants with dementia with Lewy bodies, a new study finds. The phase II trial was small, ...

Cognitive profiles for early diagnosis of Dementia with Lewy bodies (DLB) have been outlined in a new study. Although DLB is the second most common neurodegenerative dementia following Alzheimer's ...

In patients with dementia with Lewy bodies, those taking acetylcholinesterase inhibitors (with or without memantine) had a significantly lower risk of death and reduced length of hospital stay due to ...